Navigation Links
MD Biosciences Publishes the Characterization of a Porcine Model of Post-operative Or Incisional Pain in the European Journal of Pain
Date:9/25/2013

St Paul, MN (PRWEB) September 25, 2013

MD Biosciences article "Characterization of a porcine model of post-operative pain" is published in the September 2013 issue of European Journal of Pain. Dr Sigal Meilin, lead neuroscientist and research director at MD Biosciences along with colleagues developed and published a large in vivo model of post-operative pain (POP) that provides greater translational relevance for the evaluation of local treatments of POP compared with existing rodent models of incisional pain.

The management of acute pain related to surgical intervention, termed post-operative pain, continues to be a major healthcare challenge. Historically the rodent has been the model of choice for developing new analgesic treatments in the study of POP. One of the major disadvantages of the rodent model is its limited use in assessing topical and localized treatments. The anatomy of the rodent skin is also significantly different from human skin and healing occurs primarily by wound contraction rather than re-epithelialization. Porcine skin on the other hand has a higher degree of homology to human skin and heals by epidermal cell migration. There is also a considerable correlation between contracile, metabolic and morphological features in skeletal muscle of humans and pigs. The pigskin is also tightly attached to the muscle and subcutaneous tissue as in humans.

We have developed a model of post-operative pain utilizing full-skin incision or full skin and muscle incision and retraction (SIMR). We propose that this model provides greater translational relevance for local treatments compared to rodent models and enables three important parameters to be assessed in parallel:

  •     Nociceptive sensitivity
  •     Spontaneous behavior
  •     Wound healing and inflammation

MD Biosciences research group is actively involved in developing approaches, methods and models that bring greater translational relevance to the clinical situation. With greater than 90% failure rate in the clinical trial phase of drug development, more relevant models are needed that provide greater translation to the clinic. More information about the preclinical models of pain offered at MD Biosciences or access the European Journal of Pain article can be found on MD Biosciences website.

About MD Biosciences
MD Biosciences is a leading preclinical research group and contract research organization (CRO) working with biopharmaceutical and medical device companies in an effort towards progressing discovery and development programs to clinical stages. We are deeply focused on inflammatory, neurodegenerative/CNS, pain, dermal, metabolic and cardiovascular conditions with a particular emphasis on the interplay between the immune, nervous and cardiovascular systems and the conditions that arise in the cross talk between them. We bring decisive value to preclinical programs with the extensive experience gained over many years of handling different compound classes through all administration routes aimed at numerous therapeutic indications.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read the full story at http://www.prweb.com/releases/2013Sept/preclinicalPOPmodel/prweb11158440.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
2. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
3. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
4. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
5. Sangamo BioSciences Proposes Public Offering Of Common Stock
6. Rancho BioSciences Partners with OmicSoft for Manual Data Curation
7. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
8. Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
9. Rancho BioSciences Launches Rancho tranSMART Hosted for Clinical and Genomic Data Storage and Analysis
10. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):